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Abstract 
Background: Leber’s hereditary optic neuropathy (LHON) is a rare mitochondrial disorder, characterized by acute or 
subacute bilateral vision loss, frequently leading to significant chronic disability, mainly in young people. The causal 
LHON mutations of the mitochondrial DNA have incomplete penetrance, with the highest risk of disease manifesta-
tion for male mutation carriers in the second and third decades of life. Here we evaluated smoking, alcohol drinking 
habits, health-related quality of life (QOL) and psychiatric comorbidities in a cohort of LHON patients and asympto-
matic mutation carriers from a tertiary referral centre.
Methods: Cross-sectional analysis of the ongoing Munich LHON prospective cohort study. Participants included 
all LHON patients and asymptomatic LHON mutation carriers older than 16 years at baseline, who were recruited 
between February 2014 and June 2015 and consented to participate. General, neurological and ophthalmological 
investigations were performed, including validated questionnaires on smoking, alcohol drinking habits, depressive 
symptoms and health-related QOL.
Results: Seventy-one participants were included, 34 LHON patients (82% male) and 37 asymptomatic mutation 
carriers (19% male). Median age at baseline was 36 years (range 18–75 years). For LHON patients, median age at visual 
loss onset was 27 years (9 to 72 years). Smoking is more frequent in LHON patients than asymptomatic LHON muta-
tion carriers, and significantly more frequent in both groups than in the general population. Sixty percent of LHON 
patients, who smoked at disease onset, stopped or significantly reduced smoking after visual loss onset, yet 40% of 
LHON patients continued to smoke at study baseline. Excessive alcohol consumption is more frequent in male LHON 
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Open Access
*Correspondence:  andrea.rabenstein@med.uni-muenchen.de; 
tklopsto@med.LMU.de
†Andrea Rabenstein and Claudia B. Catarino contributed equally to the 
manuscript
†Tobias Rüther and Thomas Klopstock jointly supervised this work/
contributed equally to the manuscript
1 Department of Psychiatry and Psychotherapy, Ludwig-Maximilians 
University München, Nussbaumstr. 7, 80336 Munich, Germany
2 Department of Neurology, Friedrich-Baur Institute, Ludwig-Maximilians 
University München, Ziemssenstr. 1a, 80336 Munich, Germany
Full list of author information is available at the end of the article
Page 2 of 12Rabenstein et al. Orphanet J Rare Dis          (2021) 16:127 
Background
Leber’s Hereditary Optic Neuropathy (LHON, OMIM 
#535000) is one of the most frequent mitochondrial dis-
orders, with an estimated prevalence of 1:31,000 [1]. 
LHON leads to subacute bilateral vision loss, progress-
ing within weeks or months, often resulting in signifi-
cant chronic visual disability. Spontaneous recovery may 
occur, yet long-term visual outcome is often poor. Onset 
of visual loss is most frequent in male adults in the sec-
ond or third decades of life [2], although female patients, 
childhood-onset cases [3, 4] and late-onset cases [5] 
may be underdiagnosed. More than 90% of LHON is 
caused by one of three frequent point mutations of 
the mitochondrial DNA (mtDNA), m.11778G > A [6], 
m.3460G > A [7] or m.14484T > C [8], in genes coding 
subunits of complex I of the respiratory chain of the mito-
chondria [2]. Dysfunction of complex I leads to reduced 
adenosine triphosphate (ATP) production [9], increased 
reactive oxygen species, which cause dysfunction of the 
retinal ganglion cells (RGC), which are particularly sus-
ceptible to mitochondrial dysfunction, and later cause 
apoptosis of a proportion of the RGC [10]. LHON follows 
maternal inheritance with incomplete penetrance. There 
is a substantial differential risk between genders, as 50% 
of male but only 10% of female LHON mutation carriers 
may develop visual loss due to LHON in their lifetime [2]. 
This suggests a role for other genetic [11, 12] and envi-
ronmental modifiers [13–15]. Environmental factors 
add to the genetic risk and some are modifiable, such as 
smoking and excessive alcohol consumption [11]. Epide-
miological studies showed smoking is a risk factor for a 
mutation carrier to develop LHON symptoms [11]. An 
association between smoking and decreased complex I 
activity [16] suggests a mechanism for how smoking may 
aggravate genetically-determined mitochondrial dys-
function in LHON. Indeed, the risk of disease for male 
LHON mutation carriers was shown to increase from 50 
to 93% in smokers in a large epidemiological study [11, 
17]. Heavy alcohol intake has also been associated with 
a trend for increased risk of disease in LHON carriers 
[11]. Further, it has been shown that onset of visual loss 
negatively impact the quality of life of LHON mutation 
carriers [18]. A systematic analysis of health-related QOL 
and psychiatric comorbidities in a population of LHON 
patients and asymptomatic LHON mutation carriers 
has not yet been reported. With this study, we aimed to 
quantify the modifiable environmental risk factors, par-
ticularly smoking behaviour and alcohol consumption 
habits, as well as depressive symptoms and health-related 
QOL, for both LHON patients and asymptomatic LHON 
mutation carriers in a large well-characterized cohort.
Methods
Participants; LHON patients and asymptomatic LHON 
mutation carriers
Of 81 participants recruited from February 2014 to June 
2015 in the Munich LHON cohort study, 71 were 16 years 
and older at baseline and were included in the final analy-
sis. Thirty-four (48%) were LHON patients with a known 
pathogenic LHON mutation of the mtDNA and 37 (52%) 
were asymptomatic LHON mutation carriers. All partici-
pants and legal guardians (for participants under the age 
of 18) gave written informed consent or assent. The local 
Ethics committee of the Ludwig-Maximilians-University 
(LMU) of Munich approved this project (project number 
278–13).
Study design
Participants in the Munich LHON cohort study are 
examined at baseline and thereafter annually by an expert 
team of neurologists, ophthalmologists and psychiatrists 
in the outpatient clinics of the LMU University Hospi-
tal. Each visit includes thorough medical history, family 
history, as well as systematic general, neurological and 
ophthalmological examinations, and laboratory exami-
nations. Validated questionnaires on smoking habits 
and alcohol consumption, quality of life and psychiatric 
comorbidities are completed at each visit. All subjects are 
advised at each visit to quit smoking, moderate alcohol 
intake and keep a balanced diet. Information on smok-
ing cessation programmes is provided to all participants, 
who smoke.
patients than in LHON asymptomatic and more frequent than in the male general population. Further, female asymp-
tomatic LHON mutation carriers are at risk for depression and worse mental QOL scores.
Conclusions: Given the high prevalence of smoking and excessive drinking in LHON mutation carriers, implement-
ing effective measures to reduce these risk factors may have a significant impact in reducing LHON disease conver-
sion risk. The underrecognized prevalence of mental health issues in this population of LHON mutation carriers 
highlights the need for awareness and more timely diagnosis, which may lead to improved outcomes.
Keywords: Smoking, Alcohol, Mitochondrial disorder, Depression, Leber’s hereditary optic atrophy, LHON, Quality of 
life, Mental health (< 10)
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Smoking‑related data
The accuracy of self-reported smoking status was 
checked by determining the concentration of carbon 
monoxide in expired air, measured with a calibrated 
smoking meter BMC 2000 (SNEKO, Osan). Ninety-six 
percent of participants, who smoked at baseline, com-
pleted the Fagerström Test for Nicotine Dependence 
(FTND), which measures the degree of nicotine depend-
ence [19, 20]. Smoking was quantified in pack-years. A 
current smoker was defined if the participant smoked in 
the last 30 days; or ex-smoker, if they smoked more than 
100 times but not in the last 30  days; and non-smoker, 
if they smoked in total less than 100 times in life [21]. 
The proportion of smokers, for both LHON patients and 
asymptomatic LHON mutation carriers, was compared 
to the prevalence in the general population in Germany, 
stratified by gender [22].
Alcohol consumption data
The Alcohol Use Disorders Identification Test (AUDIT) 
questionnaire for detection of excessive alcohol con-
sumption [23], which includes an estimation of num-
ber of days with alcohol consumption in the previous 
30 days, and type and number of alcoholic beverages in 
an average day of alcohol consumption, was completed 
by 93% (66/71) of the participants. Total amount and 
average daily alcohol consumption were calculated for 
each participant. The alcohol-by-volume (ABV) meas-
ures used were 4.8% for beer, 11.0% for wine/sparkling 
wine and 33.0% for liquor [24]. For both groups, a quan-
tity-frequency-index was calculated as a measure of alco-
hol consumption. For all participants this was calculated 
at study baseline; and, for LHON patients, also for the 
six months preceding onset of visual loss. Excessive daily 
alcohol consumption was defined as more than 12 g/day 
for females, and 24 g/day for male participants [25]. Sev-
enty-nine percent of LHON patients and 73% of asymp-
tomatic LHON mutation carriers answered the question 
on estimated daily amount of alcohol consumption at 
study baseline.
Data collection on depressive symptoms
The Beck Depression Inventory (BDI-I) is a 21-item self-
report measure of depressive symptoms [26], which was 
completed by 88% (30/34) of LHON patients and 89% 
(33/37) of asymptomatic LHON mutation carriers. Cut-
off values were used as recommended by the current Ger-
man S3/ National health policy guidelines on depression 
[27]. The frequency of depression in both LHON patients 
and in LHON asymptomatic mutation carriers was com-
pared with the prevalence rate of depression in the gen-
eral population, which currently is 16–20% [28, 29], with 
the frequency of depressive symptoms estimated at 10.2% 
for females and 6.1% for males in the German population 
[30].
Health‑related quality of life (QOL)
Health-related QOL was assessed using the SF-12 ver-
sion 2 (SF-12 v2) questionnaire [31]. Ninety-six percent 
(68/71) of participants completed the SF-12 v2 ques-
tionnaire. Two sub-scores were calculated, the Physical 
Component Summary (PCS) and the Mental Component 
Summary (MCS). Both sub-scores were compared with 
normative data for the general population, stratified by 
gender [32].
Statistical analysis
Nominal data were compared by Chi-square tests and 
Fisher’s exact tests. Continuous data were compared by 
independent sample t-tests and one sample t-tests. As 
gender distribution was significantly different between 
LHON patients and asymptomatic LHON mutation 
carriers in our study, the statistical analyses were strati-
fied by gender. Statistical analyses were performed using 
SPSS version 25.0 for Windows (Armonk, NY:IBM Corp., 
2018). A p value of less than 0.05 was considered statisti-
cally significant.
Results
The demographic characteristics of the 71 study partici-
pants are summarized in Table 1.
Of 34 LHON patients, 28 (82%) were male (male:female 
ratio 4.7:1). Median age at study baseline was 36  years 
(range 18–75  years). Median age at clinical onset was 
27 years (range 9–72 years). Median duration of disease at 
study baseline was 2.5 years (range 4 months—37 years). 
Twenty-five LHON patients (74%) were treated with ide-
benone 900 mg/day.
Of 37 asymptomatic LHON mutation carriers, seven 
(19%) were male (male:female ratio 1:4.3), with median 
age at baseline 43 years (range 18–70 years). The gender 
distribution was significantly different between LHON 
patients and asymptomatic mutation carriers. Most 
asymptomatic LHON mutation carriers (94%) are related 
to LHON patients also included in the study.
Sixty-eight participants (96%) had one of the three pri-
mary LHON mutations of the mtDNA, and only three 
had a rare causal LHON mutation, one patient had the 
mutation m.14487  T > C [33] in the ND6 gene (n = 1) 
while one patient and one asymptomatic mutation car-
rier had the mutation m.3958G > A [34] in the ND1 gene. 
Vitamin B12 deficiency was measured at baseline or doc-
umented in the previous medical history in 44% of the 
LHON patients in our cohort.
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Table 1 Demographic characteristics and type of mutation of the participants in the present study
F, female; M, male; N/A, not applicable; SD, standard deviation; y, years; # rare causal LHON mutation: m.14487 T > C (one participant) [33]; m.3958G > A (two 
participants). *p < 0.05
LHON patients (n = 34) Asymptomatic LHON mutation carriers 
(n = 37)
Total (n = 71)
Gender, n (%)
M 28 (82%) 7 (19%) 35 (49%)
F 6 (18%) * 30 (81%)* 36 (51%)
M:F ratio 4.7:1 1:4.3 N/A
Age at study baseline (y)
Mean (± SD) 38 (± 14) 42 (± 13) 40 (± 14)
Median (range) 36 (18–75) 43 (18–70) 39 (18–75)
Age at clinical onset (y)
Mean (± SD) 31 (± 15) N/A N/A
Median (range) 27 (9–72) N/A N/A
Mutation, n (%)
m.11778G > A 23 (68%) 28 (76%) 51 (72%)
m.3460G > A 6 (18%) 4 (11%) 10 (14%)
m.14484 T > C 4 (12%) 3 (8%) 7 (10%)
Others# 1 (2%) 2 (5%) 3 (4%)
Table 2 Information on smoking behaviour at study baseline
FTND, Fagerström Test for Nicotine Dependence; SD, standard deviation
LHON patients at baseline 
(n = 34)
LHON patients before 
onset (n = 34)
Asymptomatic LHON mutation 
carriers (n = 37)
General 
population
Smoking status, n (%)
Ever-smokers 26 (76%) 23 (68%) 15 (41%)
M 22/28 (79%) 19/28 (68%) 5/7 (71%)
F 4/6 (67%) 4/6 (67%) 10/30 (33%)
Current smokers 16 (42%) 20 (59%) 12 (32%) 25%
M 14/28 (50%) 17/28 (61%) 5/7 (71%) 30%
F 2/6 (33%) 3/6 (50%) 7/30 (23%) 20%
Ex-smokers 10 (29%) 3 (9%) 3 (8%)
M 7/28 (25%) 2/28 (7%) 0/7 (0%)
F 3/6 (50%) 1/6 (12%) 3/30 (10%)
Never smokers 8 (24%) 11 (32%) 22 (59%)
M 6/28 (21%) 9/28 (32%) 2/7 (29%)
F 2/6 (33%) 2/6 (33%) 20/30 (67%)
Pack-years, for ever-smokers
Mean (± SD) 14.1 (± 13.0) 21.1 (± 14.5)
Range 0–42 0.1–102
FTND, for current smokers Nicotine 
dependence:
Very high 2 (15%) 0 (0%)
High 1 (8%) 4 (36%)
Moderate 2 (15%) 2 (18%)
Low 8 (62%) 5 (45%)
Page 5 of 12Rabenstein et al. Orphanet J Rare Dis          (2021) 16:127  
Smoking behaviour
The distribution of self-reported smoking behav-
iour for all participants is shown in Table  2. Data on 
smoking habits was available for LHON patients for the 
six months before onset of vision loss and also at study 
baseline, while for asymptomatic LHON mutation car-
riers smoking data was available only at study baseline, 
which here is equivalent to “before onset”, because per 
definition there was no visual loss onset in the asympto-
matic group.
The concentration of carbon monoxide in expired air 
correlated significantly with the self-reported daily ciga-
rette consumption (p < 0.001).
In our cohort, the proportion of ever-smokers was 
higher among LHON patients at onset than in asymp-
tomatic LHON mutation carriers (68% vs. 41%), and for 
each subgroup higher than in the general population 
(25%; p = 0.02).
Before symptom onset, 59% (20/34) of LHON patients 
and 42% (16/37) of asymptomatic LHON mutation car-
riers were current smokers, while 32% (11/34) of LHON 
patients at onset and 59% (22/37) of asymptomatic 
LHON mutation carriers were never-smokers.
For male participants, 61% (17/28) LHON patients 
before onset and 71% (5/7) asymptomatic mutation car-
riers were current smokers, which is, for both groups, 
significantly more than the frequency of smokers in the 
Table 3 Information on self-reported alcohol consumption in our cohort of LHON mutation carriers, at study baseline
Asymp., asymptomatic mutation carriers; AUDIT, Alcohol Use Disorders Identification Test; Pat., patients; SD, standard deviation





Self-reported excessive alcohol consumption before onset
(27/34 with data: 21 M/6F) 8 (30%) N/A 14%
M 7 (33%) N/A M 16%
F 1 (17%) N/A F 13%
Self-reported excessive alcohol consumption at study baseline
(64/71 with data) 7 (26%) 2 (6%) 14%
M 5 (24%) 0 (0%) M 16%
F 2 (33%) 2 (7%) F 13%
AUDIT questionnaire, n (%)
Excessive alcohol consumption at study baseline (66/71 with data:32 Pat./34 
Asymp.)
6 (19%) 4 (12%)
Daily alcohol consumption at study baseline, g/day (68/71 with data: 33 Pat./35 
Asymp.)
Mean (± SD) 12.8 (± 15.8) 6.4 (± 11.1)
Range 0–60 0–54
Days of alcohol consumption at study baseline, n (%) (68/71 with data: 33 Pat./35 
Asymp.)
Daily 3 (9.1%) 1 (2.9%)
Weekly 12 (36.4%) 10 (28.6%)
Seldom 11 (33.3%) 19 (54.3%)
Non-drinker 7 (21.2%) 5 (14.3%)
Fig. 1 Daily alcohol consumption before symptom onset, for LHON 
patients, and at baseline, for asymptomatic carriers. Average daily 
alcohol consumption (in g/day) in the six months before visual 
loss onset, for LHON patients, and at study baseline, for LHON 
asymptomatic mutation carriers. The threshold for excessive alcohol 
consumption in the general population is represented in blue for 
females (9 g/day) and red for males (16 g/day)
Page 6 of 12Rabenstein et al. Orphanet J Rare Dis          (2021) 16:127 
general male population in Germany (30%; p = 1 ×  10–5 
and p = 0.017, respectively) [22] (Additional file  1: 
Figure S1).
For female participants, 50% (3/6) LHON patients 
before onset and 23% asymptomatic LHON mutation 
carriers were current smokers, not significantly different 
to the general female population (20%) [22].
Additional file 2: Figure S2 shows a flowchart of smok-
ing behaviour over time for the LHON patients, before 
disease onset and at study baseline. While very few 
LHON patients started smoking after symptom onset and 
five LHON patients continued their smoking behaviour 
despite visual loss onset, 60% (12/20) of LHON patients, 
who had smoked at disease onset, either stopped smok-
ing or reduced smoking significantly after onset of visual 
loss. Interestingly, for about 45% of the LHON patients, 
who stopped smoking, some improvement of the visual 
acuity could be documented at last follow-up, versus 
41% of the LHON patients, who continued smoking as 
before onset, but the numbers are not sufficiently large 
for robust conclusions (Figs. 1, 2).
The FTND score, which measures the degree of nico-
tine dependence, showed no statistically significant dif-
ference between LHON patients and asymptomatic 
LHON carriers (Table 2).
Alcohol consumption
Data on alcohol consumption in our cohort is summa-
rized in Table 3, for both LHON patients and asympto-
matic LHON mutations carriers, stratified by gender.
Thirty percent (8/27) LHON patients, who filled out the 
questionnaires on alcohol consumption, reported hav-
ing had excessive alcohol consumption at disease onset 
[25]. Some LHON patients reported having reduced the 
alcohol consumption after disease onset, but the pro-
portion of male LHON mutation carriers with exces-
sive alcohol consumption (26%) at study baseline was 
still significantly higher among LHON patients than in 
asymptomatic LHON mutation carriers (p < 0.001). None 
of the five male asymptomatic LHON mutation carri-
ers reported excessive alcohol consumption. There is a 
higher proportion of male LHON patients (30%) drinking 
alcohol excessively, compared to the male general popu-
lation in Germany (15.6%) [21, 25]. This was confirmed 
by the AUDIT data, where 19% of LHON patients pre-
sented excessive alcohol consumption even at study base-
line, which was not the case for asymptomatic mutation 
carriers, as shown in Fig. 1.
Depression data
Increased depression rates in female asymptomatic LHON 
mutation carriers
For female asymptomatic LHON mutation carriers, 
44% (12/27) had mild to moderate depression, which is 
higher than the prevalence rate of depression in the Ger-
man female general population of 10.2% (28–30). No 
male asymptomatic LHON mutation carrier in this small 
subgroup (n = 7) reported depressive symptoms at study 
baseline (Table 4).
Female LHON mutation carriers at study baseline 
showed Beck Depression Inventory (BDI-I) depression 
scores, which were significantly higher for asymptomatic 
LHON carriers than for LHON patients (p = 0.02), as 
shown in Fig. 2.
For male LHON patients at study baseline, 8% (2/24) 
had mild to moderate depression, not significantly differ-
ent to the 6% frequency of the male general population. 
In the small subgroup of female LHON patients (n = 6), 
none had criteria for depression at study baseline, but we 
could not collect the more relevant data on depression at 
LHON symptom onset in our study.
Lower mental health‑related QOL in female asymptomatic 
LHON mutation carriers
Table  4 summarizes the health-related QOL data for 
our cohort of LHON patients and asymptomatic LHON 
mutation carriers, stratified by gender, as given by the 
SF-12v2. Mean PCS score was significantly lower for 
male LHON patients than the male general population 
(p = 0.015). PCS scores were also lower in the female 
LHON patients than in the female general population, 
but this was not statistically significant. For asympto-
matic LHON mutation carriers, mean PCS scores were 
significantly higher for males (p = 0.006) and females 
(p = 0.016), compared to the gender-matched general 
population.
Remarkably, the MCS score, which is a proxy for men-
tal health QOL, was lower for asymptomatic LHON 
mutation carriers than the general population (p < 0.001), 
and lower than for LHON patients at study baseline 
(p = 0.001) (Fig.  3). Interestingly, we found that female 
asymptomatic LHON mutation carriers score worse in 
mental QOL (MCS score) when compared to the female 
general population (p < 0.001). For the subgroup of female 
LHON patients, the sample is too small for robust com-
parisons. For males, there were no significant differences 
of the MCS scores, both for symptomatic and asympto-
matic groups, compared to the general population.
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Discussion
LHON is the most frequent mitochondrial disorder and 
causes a high socio-economic burden. With the present 
study, we were able to show that LHON also causes a sig-
nificant burden in mental health and quality of life, not 
only for LHON patients, but also for the asymptomatic 
at-risk relatives, who are carriers of a causal LHON 
mutation without showing symptoms.
Further, we could confirm the relevance of the previ-
ously described association between LHON and smok-
ing as a potential risk factor for LHON mutation carriers 
[11], suggesting there is potential for risk reduction by 
prophylactic interventions such as lifestyle changes in 
this population. Both LHON patients and asymptomatic 
carriers smoke significantly more than the general popu-
lation, with increased exposure to smoking described in 
large epidemiological studies to increase risk to develop 
disease. Smoking exposure for asymptomatic LHON 
mutation carriers may increase their risk of developing 
LHON, even if at the time of the study the disease may 
have not yet manifested.
Onset of visual loss in a previously asymptomatic 
LHON mutation carrier may serve as motivation to 
rethink smoking. Indeed, our data show that 60% of 
LHON patients, who were smokers at symptom onset, 
changed their smoking behaviour after experiencing 
onset of visual loss, with about a third stopping smok-
ing altogether after disease onset. We found that 45% of 
the LHON patients, who stopped smoking, showed some 
improvement of visual acuity at last follow-up, compared 
to 41% of patients, who continued smoking despite onset 
of visual loss. However, numbers are relatively small. 
Also, the percentage of idebenone intake was different 
between the groups with clinical improvement (93%) 
and without clinical improvement (65%), and other fac-
tors may have confounded this analysis, which warrants 
analysis in a larger cohort.
Sharing the diagnosis of LHON with the patient and 
the relatives, in combination with effective communi-
cation of the relevance of the modifiable risk factors, 
presents a valuable opportunity to promote smoking 
cessation, with every subsequent visit in clinic provid-
ing a renewed chance to readdress this with the patient. 
At diagnosis, the LHON patient may be more motivated 
to quit smoking, as has been previously shown in can-
cer and chronic obstructive pulmonary disease [35, 36]. 
Remarkably, one-third of LHON patients in our study 
Fig. 2 Depression data for LHON patients and asymptomatic carriers, as assessed by the BDI-I questionnaire. Box plots of depression data, as 
given by the BDI-I score, for LHON patients and asymptomatic LHON mutation carriers, stratified by gender. The whiskers represent the 95% CI. The 
thresholds in the general population are represented for females and males
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Fig. 3 Health-related quality of life for LHON patients and asymptomatic carriers, assessed by SF-12 v2 questionnaire. Box plots of the SF-12 v2 
sub-scores: Physical Component Summary (PCS, above) and Mental Component Summary (MCS, below). The whiskers represent the 95% CI. The 
thresholds in the general population are represented in blue for females (MCS 48.4 and PCS 48.7) and red for males (MCS 50.4 and PCS 50.6)
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will keep on smoking. Information on the health risks of 
smoking, but also advice and support on quitting addic-
tive behaviours should be provided to LHON patients 
and asymptomatic mutation carriers at every clinic visit.
Concordant with the previously described associa-
tion between heavy alcohol intake and increased risk of 
LHON [11], our study showed a statistically significant 
higher proportion of male LHON mutation carriers with 
excessive alcohol consumption at disease onset, com-
pared to the male general population [21]. A proportion 
of LHON patients stopped or reduced their drinking 
habits after visual loss onset, but the prevalence of exces-
sive alcohol consumption at study baseline was still more 
frequent than the prevalence of the general population.
Further, vitamin B12 deficiency was documented, 
either in the laboratory tests at baseline or in the previ-
ous medical history, in a significant proportion of the 
LHON patients in our cohort. A vitamin B12 deficiency 
may play a modulating role in the development of optic 
neuropathy, can be easily diagnosed and treated, and 
should therefore be routinely looked for in the popula-
tion of LHON mutation carriers. This warrants further 
research in a larger cohort.
To our knowledge, ours is the first study looking at 
mental health and physical health-related QOL in LHON 
mutation carriers. It had previously been shown that vis-
ual deficits in LHON negatively impact the visual-related 
QOL of LHON patients, as measured by the VF-14 scale 
[18, 37], but no study had previously systematically 
looked at the mental and physical health-related domains 
of QOL in the population of LHON mutation carriers. 
There are many dimensions to how the physical and men-
tal QOL may be impacted in a LHON mutation carrier, 
given the risk of developing severe chronic visual impair-
ment, or, for female carriers, also the risk their children 
may develop visual loss. In this study, we were able to 
show that female asymptomatic LHON mutation carriers 
score worse in mental QOL than the general population.
Further, the psychological impact of having a LHON 
mutation or becoming a patient with LHON had pre-
viously not been systematically studied. It has been 
described in the literature that men are, in general, more 
likely to develop or worsen addictive behaviours, such as 
alcoholism, whereas women are more likely to develop 
depressive symptoms, and that mental health and health-
related behaviours, such as smoking and alcohol con-
sumption, are closely linked [30, 38]. In the subgroup of 
LHON mutation carriers we have observed this, with 
male LHON patients and male asymptomatic mutation 
carriers smoking significantly more than the general 
population. Also, our study highlights a high frequency 
of mental health issues in female asymptomatic LHON 
mutation carriers, with the mental well-being of female 
asymptomatic mutation carriers shown to be worse than 
Table 4 Information on health-related quality of life (QOL) and prevalence of depressive symptoms at study baseline
BDI, Beck Depression Inventory; F, female; M, male; MCS, Mental Component Summary; N/A, not available; PCS, Physical Component Summary; SD, standard deviation; 
SF-12 v2, SF-12 version 2 questionnaire
*p < 0.05
LHON patients (n = 34) Asymptomatic LHON mutation carriers 
(n = 37)
General population
SF-12 v2 at study baseline
(68/71 with data) 33/34 35/37
MCS 49.5 ± 10.3 41.4 ± 9.5 N/A
M 48.7 (± 10.6) 50.38 (± 7.0) 50.4 (± 9.9)
F 53.3 (± 8.9) 39.59 (± 8.9)* 48.4 (± 9.6)
PCS 46.7 ± 6.9 54.3 ± 9.6 N/A
M 47.3 (± 6.6) 57.1 (± 3.5)* 50.6 (± 10.2)
F 43.9 (± 8.4) 53.7 (± 10.4) 48.7 (± 9.6)
BDI at study baseline
(63/71 with data) 30/34 33/37
Depressive symptoms:
Severe 0 0 (Depression 
16–20%;10% F; 
6% M))
Moderate 2 (7%) [2M] 2 (6%) [2F]
Mild 0 10 (30%) [10F]
Depression score 4.5 ± 6.0 8.1 ± 6.0*
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the female general population. Further, we found that 
mild and moderate depression is more frequent in female 
asymptomatic mutation carriers. It can be expected that 
screening the mental health of this population may allow 
earlier identification and treatment of mental health 
issues. These may be compounded by the stress of having 
an affected relative, uncertainty given the risk of develop-
ing the disease, with consequent vision loss and disabil-
ity, as well as uncertainty given the risk for their children. 
Our findings on QOL and on depression are consistent, 
for LHON patients and asymptomatic mutation carri-
ers. Depressive symptoms are known to have a negative 
impact on health-related QOL [39]. Enhancing indi-
vidual health-related QOL is an important therapeutic 
goal of every treatment and this is relevant when treat-
ing and counselling both LHON patients and asympto-
matic LHON mutation carriers. In general, it has been 
described that people with psychiatric comorbidities, 
especially those with depressive symptoms, are more 
likely to be non-compliant to medical recommendations 
[40] and poor mental health is associated with health-
related behaviours such as smoking, physical inactiv-
ity and poor nutrition [41]. In our study we did not look 
systematically at nutrition, physical activity and compli-
ance to medical recommendations, for LHON mutation 
carriers.
Our study has some limitations. The data we collected 
on depression and QOL for the LHON patients reports 
to the study baseline, which occurred from 4 months to 
36 years after onset of visual loss, which may mean that 
at least a proportion of LHON patients may already have 
readjusted [18], and, therefore, we may underestimate 
the real impact of depression and mental health issues 
in LHON patients. There is significant phenotypical 
heterogeneity in LHON and a large spectrum of disease 
severity and disability, with a proportion of patients hav-
ing significant clinical improvement, others no clinical 
improvement whatsoever and severe visual loss, which 
may influence QOL and psychological impact of dis-
ease. LHON patients would be expected to have higher 
depression scores than what we found, if the question-
naires had been administered sooner after symptom 
onset, when they first start experiencing visual loss or 
shortly thereafter. After several months or years, some 
LHON patients may already had time to adapt to the 
new condition, therefore this analysis performed at study 
baseline may underestimate the frequency of depres-
sion in the LHON patients. Further, the data on alcohol 
consumption was self-reported, which may have yielded 
underreporting for some patients. Another limitation of 
our study is that published data on the general popula-
tion was used for comparison, given the small size of our 
group of healthy controls, which did not allow robust 
statistical comparisons. Although our LHON cohort 
study has been set up longitudinally, the current study is 
based on the cross-sectional analysis of the baseline data 
of the subjects enrolled in the first two years. We cannot 
know at study baseline whether and when any asympto-
matic mutation carrier will develop LHON disease in the 
future. Further, some recall bias can be expected for the 
retrospective self-reported data on smoking and alco-
hol consumption before clinical onset of LHON, making 
the information on exposure to environmental triggers 
before clinical onset, its duration and quantification, less 
accurate, even more so for LHON patients with longer 
disease duration.
Conclusions
Our study provides insights on lifestyle factors, psychiat-
ric comorbidities, health-related QOL and psychological 
impact in both LHON patients and asymptomatic LHON 
mutation carriers. The high prevalence of smoking in 
LHON mutation carriers and excessive alcohol con-
sumption in male LHON mutation carriers emphasizes 
the chance for effective prophylactic measures in the 
population of LHON mutation carriers, which may have 
a significant impact on future risk of disease manifesta-
tion and prognosis. We could show that female asympto-
matic LHON mutation carriers are at particular risk for 
mental health issues. Promoting mental health in LHON 
mutation carriers may be expected to lead to more timely 
treatment and have a positive impact in mental health 
and QOL in LHON mutation carriers.
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